10th European Congress on Perspectives in Lung Cancer, Brussels

Published: July 21, 2009, 6:57 p.m.

Silvia Novello and Giorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity of figitumumab to be at least as good as that of inhibitors of other growth factors already being used in cancer.